Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation

(2010) E. T. Ogburn et al.   DRUG METABOLISM AND DISPOSITION

Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin

(2009) Matthijs van Luin et al.   AIDS

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

CYP2B6(c.516G→T) andCYP2A6(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

(2009) Awewura Kwara et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine

(2009) A.-S. Belanger et al.   DRUG METABOLISM AND DISPOSITION

Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis

(2009) Yuan Ren et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

(2009) Julia di Iulio et al.   Pharmacogenetics and Genomics